{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:43:31Z","timestamp":1792763011904,"version":"4.5.0"},"reference-count":11,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,10,11]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/bcr-2026-275020","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:35:22Z","timestamp":1792762522000},"page":"e275020","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Synchronous rearranged during transfection fusion-positive lung adenocarcinoma and anaplastic lymphoma kinase-positive inflammatory myofibroblastic tumour"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7838-6586","authenticated-orcid":false,"given":"Eva","family":"Nee","sequence":"first","affiliation":[{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghunandan","family":"Nayak","sequence":"additional","affiliation":[{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"},{"name":"Northwell Health, New Hyde Park, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3282-7622","authenticated-orcid":false,"given":"Nagashree","family":"Seetharamu","sequence":"additional","affiliation":[{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"},{"name":"Northwell Health, New Hyde Park, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"2026102306351437000_19.10.e275020.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.021"},{"key":"2026102306351437000_19.10.e275020.2","article-title":"Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC","volume":"6","author":"Zhou","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"2026102306351437000_19.10.e275020.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309457"},{"key":"2026102306351437000_19.10.e275020.4","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s11864-023-01144-6","article-title":"Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor","volume":"24","author":"Wang","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"2026102306351437000_19.10.e275020.5","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0224","article-title":"Mechanisms of resistance to RET-directed therapies","volume":"32","author":"Clifton-Bligh","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"2026102306351437000_19.10.e275020.6","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jtho.2022.06.008","article-title":"Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy","volume":"17","author":"Kalchiem-Dekel","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026102306351437000_19.10.e275020.7","doi-asserted-by":"crossref","unstructured":"Paula AG , Liu X , Heeke S , et al . Chylopericardium and chylous effusions during treatment with selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC). JCO 2025;43. doi:10.1200\/JCO.2025.43.16_suppl.e20694","DOI":"10.1200\/JCO.2025.43.16_suppl.e20694"},{"key":"2026102306351437000_19.10.e275020.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187"},{"key":"2026102306351437000_19.10.e275020.9","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/oncolo\/oyae282","article-title":"Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time","volume":"29","author":"Raez","year":"2024","journal-title":"Oncologist"},{"key":"2026102306351437000_19.10.e275020.10","doi-asserted-by":"crossref","first-page":"107535","DOI":"10.1016\/j.lungcan.2024.107535","article-title":"A pragmatic guide for management of adverse events associated with lorlatinib","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"key":"2026102306351437000_19.10.e275020.11","unstructured":"Pfizer Inc . LORBRENA (lorlatinib) tablets, for oral use: prescribing information. New York (NY): Pfizer Inc, U.S. Food and Drug Administration; 2021."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-275020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:35:24Z","timestamp":1792762524000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-275020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,23]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bcr-2026-275020"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-275020","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}